NeuroPace (NPCE) News Today $7.20 +0.03 (+0.42%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 5 at 5:52 PM | markets.businessinsider.comNeuroPace (NPCE) Gets a Buy from Lake StreetSeptember 4 at 4:05 PM | globenewswire.comNeuroPace Strengthens Management Team with Two Key AppointmentsAugust 27, 2024 | globenewswire.comNeuroPace Announces Participation at Two Upcoming Healthcare Investor ConferencesAugust 22, 2024 | globenewswire.comNeuroPace to Participate in Upcoming Healthcare Conferences in SeptemberAugust 20, 2024 | seekingalpha.comNeuroPace: Only For Those With Strong NervesAugust 19, 2024 | marketbeat.comResearch Analysts Set Expectations for NeuroPace, Inc.'s FY2024 Earnings (NASDAQ:NPCE)NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of NeuroPace in a research report issued on Wednesday, August 14th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings per share of (August 17, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Position Raised by Vanguard Group Inc.Vanguard Group Inc. boosted its position in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 18.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 488,618 shares of the company's stock after purchasing an additional 75,51August 17, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation toAugust 16, 2024 | markets.businessinsider.comNeuroPace: Strong Q2 Performance and Promising Future Drive ‘Outperform’ RatingAugust 16, 2024 | finance.yahoo.comEarnings Release: Here's Why Analysts Cut Their NeuroPace, Inc. (NASDAQ:NPCE) Price Target To US$14.57August 16, 2024 | marketbeat.comQ3 2024 Earnings Estimate for NeuroPace, Inc. (NASDAQ:NPCE) Issued By Leerink PartnrsNeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Stock analysts at Leerink Partnrs boosted their Q3 2024 earnings per share (EPS) estimates for NeuroPace in a research report issued on Tuesday, August 13th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per shaAugust 15, 2024 | finanznachrichten.deNeuroPace, Inc.: NeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceAugust 14, 2024 | marketbeat.comNeuroPace (NASDAQ:NPCE) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPSNeuroPace (NASDAQ:NPCE - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.03. The business had revenue of $19.26 million for the quarter, compared to analyst estimates of $18.30 million. NeuroPace had a negative return on equity of 173.62% and a negative net margin of 45.61%. The business's revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.36) EPS.August 14, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for NeuroPace (NASDAQ:NPCE)Cantor Fitzgerald reissued an "overweight" rating and issued a $18.00 target price on shares of NeuroPace in a research report on Wednesday.August 14, 2024 | marketbeat.comNeuroPace (NASDAQ:NPCE) PT Lowered to $15.00Wells Fargo & Company reduced their price target on NeuroPace from $20.00 to $15.00 and set an "overweight" rating on the stock in a research report on Wednesday.August 14, 2024 | finance.yahoo.comNeuroPace Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceAugust 13, 2024 | markets.businessinsider.comNeuroPace earnings: here's what Wall Street expectsAugust 6, 2024 | marketbeat.comNeuroPace (NPCE) to Release Quarterly Earnings on TuesdayNeuroPace (NASDAQ:NPCE) will be releasing earnings after the market closes on Tuesday, August 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=611719)July 23, 2024 | globenewswire.comNeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024June 28, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has earned an average rating of "Moderate Buy" from the seven analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the companJune 13, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Sees Significant Decrease in Short InterestNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 74,200 shares, a decline of 40.9% from the May 15th total of 125,500 shares. Based on an average daily volume of 114,000 shares, the short-interest ratio is presently 0.7 days. Approximately 0.5% of the company's shares are short sold.June 3, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by BrokeragesNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1May 29, 2024 | markets.businessinsider.comStrong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPaceMay 27, 2024 | finance.yahoo.comNeuroPace, Inc.'s (NASDAQ:NPCE) top owners are private equity firms with 47% stake, while 24% is held by institutionsMay 14, 2024 | finance.yahoo.comNeuroPace to Participate in Two Healthcare Conferences in MayMay 13, 2024 | finance.yahoo.comNeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings: Revenue Surpasses Estimates Amidst Ongoing ChallengesMay 10, 2024 | marketbeat.comResearch Analysts Issue Forecasts for NeuroPace, Inc.'s FY2028 Earnings (NASDAQ:NPCE)NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for shares of NeuroPace in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of $0.27 fMay 10, 2024 | markets.businessinsider.comNeuroPace’s Strong Q1 Performance and Promising Growth Prospects Affirm Buy RatingMay 9, 2024 | marketbeat.comTrading was temporarily halted for "NPCE" at 09:05 AM with a stated reason of "LULD pause."May 9, 2024 | finanznachrichten.deNeuroPace, Inc: NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | finance.yahoo.comNeuroPace Inc (NPCE) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 8, 2024 | msn.comNeuroPace GAAP EPS of -$0.32May 8, 2024 | globenewswire.comNeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comNeuroPace is about to announce its earnings — here's what Wall Street expectsMay 4, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 4,674 Shares of StockApril 27, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 1,781 SharesApril 24, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $345,756.45 in StockApril 23, 2024 | marketbeat.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 24,609 Shares of StockNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 24,609 shares of the stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $14.05, for a total value of $345,756.45. Following the sale, the insider now owns 3,459,113 shares in the company, valued at approximately $48,600,537.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.April 20, 2024 | investing.comOrbiMed Advisors sells shares in NeuroPace worth over $238,000April 19, 2024 | insidertrades.comInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of StockApril 18, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in StockNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 2,623 shares of the company's stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $14.06, for a total transaction of $36,879.38. Following the sale, the insider now directly owns 3,501,975 shares in the company, valued at $49,237,768.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.April 17, 2024 | globenewswire.comNeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024April 16, 2024 | insidertrades.comNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in StockApril 15, 2024 | marketbeat.comOrbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockNeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) major shareholder Orbimed Advisors Llc sold 461,899 shares of the firm's stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $14.49, for a total value of $6,692,916.51. Following the completion of the sale, the insider now owns 3,542,068 shares in the company, valued at $51,324,565.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.April 14, 2024 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy ratApril 12, 2024 | marketbeat.comShort Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 85,900 shares, a growth of 178.0% from the March 15th total of 30,900 shares. Currently, 0.7% of the company's shares are short sold. Based on an average trading volume of 98,900 shares, the short-interest ratio is currently 0.9 days.April 10, 2024 | fool.comNeuroPace (NASDAQ: NPCE)April 6, 2024 | marketbeat.comKent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)Kent Lake Capital LLC grew its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 16.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 670,946 shares of the company's stock after acquiring an additional 96,529 shares during theApril 4, 2024 | msn.com'Biggest mistake' bond investors may make ahead of Fed rate cuts Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden's Successor: The Radical Threat to YOUR Savings! (Ad)Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL. >> Get Your FREE Wealth Protection Guide << NPCE Media Mentions By Week NPCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NPCE News Sentiment▼0.000.55▲Average Medical News Sentiment NPCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NPCE Articles This Week▼22▲NPCE Articles Average Week Get NeuroPace News Delivered to You Automatically Sign up to receive the latest news and ratings for NPCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Utah Medical Products News TELA Bio News Beyond Air News PAVmed News National Vision News Bioventus News OrthoPediatrics News Liquidia News Paragon 28 News SI-BONE News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NPCE) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroPace, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroPace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.